Abrilumab

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameAbrilumab
Drug Alias NameabrilimumabMEDI-7183AMG-181
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionIntegrin alpha-4/beta-7 antagonistsImmunomodulators
TargetsIntegrin alpha-4/beta-7
Therapy Area/IndicationsCrohn DiseaseColitis, Ulcerative
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[22] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstrazeneca PlcAmgen Inc
Active IndicationsN/A
Inactive IndicationsCrohn DiseaseColitis, Ulcerative

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG